National Health Investors (NHI) EBITDA (2009 - 2022)

National Health Investors has reported EBITDA for 14 years, with the latest figure at $8.2 million in Q1 2022.

• For the quarter ending Q1 2022, EBITDA fell 77.81% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2022 stood at $132.2 million (down 33.16% YoY), and the FY2021 full-year result was $8.2 million, down 77.81% from the prior year.
• EBITDA for Q1 2022 stood at $8.2 million, down from $41.0 million in the prior quarter.
• The five-year high for EBITDA was $62.4 million in Q3 2019, with the low at $8.2 million in Q1 2022.
• Historically, EBITDA has averaged $41.5 million across 5 years, with a median of $40.4 million in 2018.
• Annual changes were most pronounced in 2020 — EBITDA surged 50.81% — and 2022, when it sank 77.81%.
• National Health Investors' EBITDA stood at $59.1 million in 2018, then climbed by 5.61% to $62.4 million in 2019, then fell by 26.63% to $45.8 million in 2020, then slipped by 10.58% to $41.0 million in 2021, then tumbled by 79.88% to $8.2 million in 2022.
• The last three EBITDA figures came in at $8.2 million (Q1 2022), $41.0 million (Q2 2021), and $37.2 million (Q1 2021), per Business Quant data.